Respiratory Disease Testing Market Size By Test Type (Mechanical Tests {Spirometry, Peak-flow Test, Pulmonary Function Test, Blood Gas Test), Imaging Tests {X-ray, CT-scan, Ultrasonography, MRI}, In-vitro Diagnostic Tests {Point-of-care Test, Molecular Di

Respiratory Disease Testing Market Size By Test Type (Mechanical Tests {Spirometry, Peak-flow Test, Pulmonary Function Test, Blood Gas Test), Imaging Tests {X-ray, CT-scan, Ultrasonography, MRI}, In-vitro Diagnostic Tests {Point-of-care Test, Molecular Diagnostic Test}), By Application (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis) By End-use (Diagnostic Centers, Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 - 2026

The respiratory disease testing market is set to witness significant growth over the coming years owing to the increasing prevalence of lung diseases caused by infections or smoking tobacco. Respiratory diseases are types of ailments that affects lungs as well as other portions of the overall respiratory system.

These respiratory diseases could be caused by smoking tobacco, infection, breathing in second-hand tobacco smoke, asbestos, radon, or some other air pollutants. Some of the most common respiratory diseases include chronic obstructive pulmonary disease, asthma, pneumonia, pulmonary fibrosis, and lung cancer.

Respiratory illnesses are a common problem for a majority of people across the globe. Often, individuals are genetically more inclined to develop respiratory conditions. However, it has been proven that the workplace conditions and environmental exposures can also play a vital role in people developing respiratory issues. Apart from these factors, smoking is classified as the most common determinant that causes respiratory diseases.

The overall respiratory disease testing market is bifurcated in terms of test type, application, end-use, and regional landscape.

The test type segment is further classified in terms of mechanical tests, imaging tests, and invitro diagnostics tests. Among these, the imaging test segment is set to register significant traction. The demand for imaging modalities has risen in the past few months due to the outbreak of novel coronavirus infection. These methods are extremely useful to identify the new cases caused by COVID-19 outbreak, thus, escalating the respiratory disease testing industry growth. For instance, in Spain, chest X-ray was the first imaging method to diagnose COVID-19 infection.

Based on application, the market is divided into chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and other diseases. Among these the tuberculosis segment is likely to register tremendous growth over the forecast timeframe. Tuberculosis results in 1.5 million deaths and is most common in developing countries such as South Africa, Cambodia, Congo and others.

In terms of end-use landscape, the market is divided into diagnostic centers, hospitals, clinics, and others. The availability of various imaging modalities with the various mechanical tests makes hospitals more preferable to patients, enabling the hospitals segment to witness prominent growth. Additionally, medical tie-ups with hospitals will further drive the market outlook.

From a regional reference frame, the Asia Pacific respiratory disease testing market is set to register tremendous growth in coming years. India and China are expected to be the most lucrative countries in the Asia Pacific region due to the increasing cases of respiratory disorders coupled with the favorable reimbursement scenario being introduced.